Loading
A phase 2 trial of Adagrasib, Pembrolizumab, Cetuximab, Pemetrexed, Docetaxel and Oxaliplatin in advanced solid tumours, run by Mirati Therapeutics Inc., now recruiting.
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies is a phase 2 interventional study registered as NCT07415031 by Mirati Therapeutics Inc., with 170 participants planned, started 2026-05-06 and due to reach its primary completion in 2028-02-16. Interventions recorded: Adagrasib, Pembrolizumab, Cetuximab, Pemetrexed, Docetaxel and Irinotecan.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Adagrasib, KRAS & RAS inhibitors, Pemetrexed, Bristol Myers Squibb and the tag pipeline.
Shares Adagrasib, KRAS & RAS inhibitors, Pemetrexed, Bristol Myers Squibb and the tag pipeline.
Shares Cetuximab, Pemetrexed, Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Oxaliplatin, Pemetrexed, Docetaxel, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Cetuximab, Pemetrexed, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pemetrexed, Docetaxel, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Cetuximab, Pembrolizumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/